As of March 26, we're $27,100 in the red for the quarter. Donate here to support this vital work
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Ebola Contracts Worth $2 Billion Could Benefit Drugmakers
Key Excerpts from Article on Website of Bloomberg


Bloomberg, November 10, 2014
Posted: November 16th, 2014
http://www.bloomberg.com/news/2014-11-10/ebola-contracts-wor...

Drugmakers including Mapp Biopharmaceutical Inc., Johnson & Johnson and Emergent Biosolutions Inc. (EBS) are among companies standing to gain from what may be $2 billion in U.S. contracts related to Ebola. President Barack Obama asked Congress last week for $6.2 billion in emergency funding to stop the spread of the virus that has killed more than 4,800 people in West Africa. The request is heavily focused on health needs as opposed to prior funding that was largely centered on defense contracts, Brian Friel, a Bloomberg Intelligence contracts analyst, said. Friel said he expects multiple drugmakers involved in Ebola will share in what will likely be no-bid contract awards to make everyone happy. His $2 billion estimate is based on the percentage of its budget the Department of Health and Human Services spent on contracts last year. Little information is available yet about which companies are getting Ebola-related public funding. Congress has approved $838 million in Ebola money this year, resulting in $77 million in contracts so far. Not all awards have been made public. The U.S. has spent more than $400 million as of Oct. 24.

Note: Read this webpage which lays bare the gross profiteering by pharmaceuticals on pandemics like ebola as reported in the mainstream media.


Latest News


Key News Articles from Years Past